Eiger's Lonafarnib Loses EU Fast-Track Review Status

Potential Progeria Treatment Has Reverted To Standard Review

Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.

Progeria: do you know about it?
Progeria is an extremely rare and fatal premature aging syndrome • Source: Shutterstock

Lonafarnib, Eiger BioPharmaceuticals’ investigational treatment for progeria and progeroid laminopathies, has lost its accelerated assessment status at the European Medicines Agency. The EU marketing authorization application (MAA) for the oral farnesyltransferase inhibitor will now be reviewed under standard timelines.

The US company attributed the change in review status to the EMA's desire to carry out an inspection and to...

More from Europe

More from Geography